ESR1 and breast cancer: The multiplexing capability of the SERS nanotags (characteristic Raman reporters modified 40 nm Au NPs) has been demonstrated for the simultaneous recognition of ER, PR, and HER2 in breast cancer cell lines and tissue samples, offering a rapid and accurate method for prognostic analysis (Figure 9A) [130].